



Postoperative Complications in Intrahepatic Cholangiocarcinoma Surgery

Fazio Luixe*

Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China

DESCRIPTION

Intrahepatic Cholangiocarcinoma (ICC) is a type of liver cancer originating from the bile ducts within the liver. As one of the most aggressive and challenging hepatobiliary malignancies, ICC has historically been associated with poor prognosis due to its tendency for late diagnosis and high recurrence rates. Among the therapeutic strategies for managing ICC, surgery remains the cornerstone for potentially curative treatment. Upfront surgery, which refers to immediate surgical resection without prior systemic therapy, is considered the primary treatment for patients with resectable tumors. This article discusses the role, outcomes and considerations of upfront surgery in the treatment of intrahepatic cholangiocarcinoma.

ICC accounts for approximately 10%-15% of primary liver cancers, making it the second most common type of liver malignancy after hepatocellular carcinoma. The tumor arises from the epithelial cells lining the intrahepatic bile ducts and it is characterized by its aggressive growth and tendency to metastasize. Due to the anatomical complexity of the liver and bile ducts, as well as the lack of early clinical symptoms, ICC is often diagnosed at an advanced stage. This complicates treatment strategies and reduces the chances of long-term survival [1-4].

Patients with ICC typically present with vague or nonspecific symptoms such as abdominal pain, jaundice, weight loss and fatigue. These symptoms are often mistaken for other liver or gastrointestinal conditions, leading to delays in diagnosis. As a result, a significant proportion of patients are not candidates for curative surgery at the time of diagnosis due to the presence of advanced disease, vascular invasion, or distant metastases [5-7].

Surgical resection is currently the only potentially curative treatment for patients with ICC and upfront surgery is pursued in cases where the tumor is considered resectable at the time of diagnosis. Resectability is determined by several factors, including tumor size, location, proximity to vital structures (such as the hepatic vasculature) and the presence of metastases. In

general, patients with localized disease and without evidence of metastasis are considered candidates for surgery.

The goal of upfront surgery is to achieve a complete resection (R0 resection), meaning that all visible tumor tissue is removed and there are no cancer cells at the resection margins. Achieving an R0 resection is critical for improving long-term survival outcomes, as incomplete resection (R1 or R2) is associated with a higher risk of recurrence and poorer prognosis [8-10].

Hepatectomy, or the surgical removal of part of the liver, is the standard procedure for patients with resectable ICC. Depending on the location and extent of the tumor, a minor or major hepatectomy may be required. In some cases, additional procedures, such as bile duct resection or vascular reconstruction, may be necessary to achieve a complete resection.

Performing liver surgery for ICC presents several unique challenges due to the complex anatomy of the liver and its vascular structures. The liver is divided into eight segments, each with its own blood supply and bile ducts. Tumors that are located near the major vessels, such as the portal vein or hepatic artery, can be particularly difficult to remove without causing significant damage to the liver's blood supply. Surgeons must carefully plan the resection to preserve enough healthy liver tissue while ensuring that all tumor tissue is removed.

In addition to anatomical considerations, surgeons must evaluate the patient's overall liver function before proceeding with resection. Many patients with ICC have underlying liver diseases, such as cirrhosis or hepatitis, which can affect their ability to tolerate surgery. Preoperative liver function tests, imaging studies and functional assessments are critical in determining the safety and feasibility of surgery.

Another challenge in the surgical management of ICC is the high rate of postoperative complications. Hepatectomy is a major surgery that carries risks such as bleeding, bile leaks and liver failure. Patients with preexisting liver disease or poor nutritional status are at an increased risk of complications, which can affect recovery and long-term outcomes. Close postoperative

Correspondence to: Fazio Luixe, Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China, E-mail: fazio@luixe.cn

Received: 26-Aug-2024, Manuscript No. JSA-24-27055; **Editor assigned:** 28-Aug-2024, PreQC No. JSA-24-27055 (PQ); **Reviewed:** 11-Sep-2024, QC No. JSA-24-27055; **Revised:** 19-Sep-2024, Manuscript No. JSA-24-27055 (R); **Published:** 26-Sep-2024, DOI: 10.35248/2684-1606.24.8.264

Citation: Luixe F (2024). Postoperative Complications in Intrahepatic Cholangiocarcinoma Surgery. *J Surg Anesth.* 8:264.

Copyright: © 2024 Luixe F. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

monitoring and supportive care are essential to manage these complications and ensure optimal recovery.

Conclusion

Upfront surgery is currently the most effective curative treatment for intrahepatic cholangiocarcinoma in patients with resectable disease. However, the aggressive nature of ICC, coupled with high recurrence rates, makes long-term survival challenging. Achieving a complete resection is critical for improving outcomes, but the risk of postoperative complications and recurrence remains significant.

Adjuvant therapies and close postoperative surveillance are important components of the treatment strategy to reduce recurrence and prolong survival. Ongoing research into novel therapies, including targeted treatments and immunotherapies, offers hope for improving outcomes in patients with ICC. As new treatment options emerge, a multidisciplinary approach that combines surgery with systemic therapies and rigorous follow-up will be essential in managing this complex disease.

REFERENCES

1. Woulfe F, Devine M, Hayes B, Crotty R, O'Sullivan A. A case report of primary intrahepatic adeno squamous cell cholangiocarcinoma. *Int J Surg Case Rep.* 2024;110366.
2. Peng YC, Liao SH, Tsai JH, Chen PT, Chang CC, Kao JH, et al. Comparison of the clinicoradiological features and outcomes of lymphoepithelioma-like cholangiocarcinoma and conventional intrahepatic cholangiocarcinoma: A propensity score matching analysis. *J Formos Med Assoc.* 2024.
3. Wang SH, Hsieh YY, Ong KH, Lai HY, Tsai HH, Sun DP, et al. The clinicopathological significance and prognostic impact of 14-3-3 σ /stratify expression on patients with surgically resectable intrahepatic cholangiocarcinoma. *Asian J Surg.* 2024.
4. Huang W, Lv TR, Bai L, Tang H. The significance of neuroendocrine component in cases with intrahepatic cholangiocarcinoma: A SEER-based retrospective cohort study. *Curr Probl Surg.* 2024;101608.
5. Goel M, Varty GP, Patkar S, Meghana V, Kazi M, Nandy K, et al. Preventing futile surgery in Intrahepatic and Perihilar cholangiocarcinomas: Can we identify preoperative factors to improve patient selection and optimize outcomes?. *Surg Oncol.* 2024;55:102096.
6. Kendall T, Overi D, Guido M, Braconi C, Banales J, Cardinale V, et al. Recommendations on maximising the clinical value of tissue in the management of patients with intrahepatic cholangiocarcinoma. *JHEP Rep.* 2024;6(6):101067.
7. Sheng R, Zheng B, He D, Sun W, Zhang Y, Yang C, et al. Tumor apparent diffusion coefficient is associated with early recurrence of intrahepatic cholangiocarcinoma. *Acad Radiol.* 2024.
8. Song F, Wang CG, Wang TL, Tao YC, Mao JZ, Hu CW, et al. Enhancement of gemcitabine sensitivity in intrahepatic cholangiocarcinoma through Saikosaponin-a mediated modulation of the p-AKT/BCL-6/ABCA1 axis. *Phytomedicine.* 2024;133:155944.
9. Gavrilă GA, Dan AA, Smarandache CG. Complete regression of intrahepatic cholangiocarcinoma after right portal vein ligation. Case report. *Int J Surg Case Rep.* 2024;117:109580.
10. Liang Y, Bu Q, You W, Zhang R, Xu Z, Gan X, et al. Single-cell analysis reveals hypoxia-induced immunosuppressive microenvironment in intrahepatic cholangiocarcinoma. *Biochim Biophys Acta Mol Basis Dis.* 2024;167276.